Homepage - Policy Center for Maternal Mental Health

2025 Maternal Mental Health FORUM

At the intersection of Policy, Payment & Practice

You won’t want to miss the 2025 FORUM, where cross-sector change agents will gather to drive change in maternal mental health.
The Maternal Mental Health FORUM
Every Mother, Every Time

It’s time for a U.S. healthcare system that detects and treats maternal mental health disorders

We identify barriers, find solutions and catalyze lasting systems change
Our Work
20% of maternal deaths are due to suicide

20% of the perinatal population will suffer from an MMH disorder

Less than 20% will be screened or get the care they need
Learn More
96% of birthing-age, American women

live in maternal mental health professional shortage areas

this not only leaves mothers with no treatment options, but is also commonly noted by health insurance plans as the reason for their insufficient provider networks
Learn More

pol·i·cy

A rule or plan of action, adopted and followed by a group, organization, or government

We are a policy think tank and field catalyst. We inform and facilitate systems change to improve women’s mental health during the childbearing years so that mothers, children, and families have the best opportunity to thrive.

Learn More

key players

We directly serve, cross-sector leaders & change agents in the U.S.

Policy Makers

·Law Makers
·Regulators Addressing
·Health Policy

Learn More

Providers

·Obstetricians/Midwives
·Hospital/Health Systems

Learn More

Payors

·Insurers
·Health Plans
·Employers
·Medicaid Agencies

Learn More

Affecting all mothers

Maternal Mental Health Disorders are the most common complications of pregnancy

They impact, on average:

up to

1 in 5

Of the expecting and postpartum mothers in the U.S., mothers of color suffer at higher rates.

96% of the perinatal population

lives in a Maternal Mental Health Shortage Area.

Identifying the most vulnerable mothers without access to care

Read the Report

The Latest news

View All

Blog

Dec 9, 2024

Are Maternal Mental Health Digital Therapeutics Ready for Prime Time?

To date, U.S. adoption of DTX has been slow due to limited…

Blog

Dec 6, 2024

My Remarks at the Axios Improving Postpartum Care Event

On Wednesday, December 4, the Policy Center presented an Axios media event…

Report

Dec 4, 2024

One Year Later: How Insurers Are Covering Zurzuvae, the First Postpartum Depression Pill

It’s been a year since Zurzuvae™, the first oral postpartum depression drug…

Blog

Dec 2, 2024

New Psychedelic for Postpartum Depression Now Being Studied

In 2024, Reunion Neuroscience announced the launch of phase 2 of the…

Blog

Dec 9, 2024
Are Maternal Mental Health Digital Therapeutics Ready for Prime Time?
To date, U.S. adoption of DTX has been slow due to limited insurance reimbursement structures, lack of integration into healthcare systems, and low patient awareness. That’s a challenge because DTX could significantly impact healthcare by offering patients non-pharmaceutical alternative treatment options that can be more efficiently monitored and providing economic benefits for providers by introducing new and more frequent billing opportunities….

Read More
Blog

Dec 6, 2024
My Remarks at the Axios Improving Postpartum Care Event
On Wednesday, December 4, the Policy Center presented an Axios media event titled “Improving Postpartum Care” in the U.S. Here are our CEO, Joy Burkhard’s remarks, including a question and answer that didn’t make it into the segment. …

Read More
Report

Dec 4, 2024
One Year Later: How Insurers Are Covering Zurzuvae, the First Postpartum Depression Pill
It’s been a year since Zurzuvae™, the first oral postpartum depression drug treatment, became FDA-approved. Initially, very few insurers/payers had published coverage guidelines. Now nearly all have published guidelines, and most provide reasonable access to Zurzuvae….

Read More
Blog

Dec 2, 2024
New Psychedelic for Postpartum Depression Now Being Studied
In 2024, Reunion Neuroscience announced the launch of phase 2 of the RECONNECT clinical trial, a psychedelic treatment for postpartum depression (PPD). The clinical trial began in July of this year and the trial is expected to end in 2025. …

Read More